On this page
Incontinentia pigmenti
This condition mainly impacts females and can also affect hair, teeth, nails, eyes, and the central nervous system. It is present from birth, with symptoms changing over time, and is caused by genetic changes in the IKBKG gene.
Overview
Incontinentia pigmenti (IP) is a rare genetic condition predominantly affecting the skin, with characteristic patterns that evolve over time. It typically manifests at or shortly after birth, progressing through stages of rashes, blisters, wart-like growths, and eventually distinctive swirling patterns of increased skin pigmentation [PMID:33678502]. While the skin is most commonly affected, IP can also involve the hair, teeth, nails, eyes, and central nervous system. The severity and combination of these features can vary significantly among affected individuals.
This condition is much more frequently observed in females. Males with the genetic alteration causing IP often do not survive to term due to the severe impact of the condition. IP was first described in 1906, and its understanding has developed considerably since then, including the identification of its genetic basis.
Symptoms & clinical features
The symptoms of incontinentia pigmenti typically progress through four main stages in the skin, although not all individuals experience every stage or in the same order. The first stage usually involves blistering rashes, often appearing at birth or in early infancy. These blisters may heal, giving way to the second stage, characterised by wart-like growths (verrucous lesions).
The third stage is marked by hyperpigmentation - areas of increased skin colour - forming grey-brown, swirling patterns, often described as 'splashes of mud'. These patterns are particularly noticeable on the trunk and limbs. The final stage, which can occur later in childhood or adulthood, involves hypopigmentation (areas of lighter skin), skin atrophy (thinning), and scarring. Beyond the skin, other common symptoms include sparse hair, missing or abnormally shaped teeth, and brittle or ridged nails. In some cases, there can be eye abnormalities, such as retinal detachment, and neurological issues like seizures or developmental delay, though these are less common [PMID:33678502].
Video: Genetics 101
Affected organs
Incontinentia pigmenti primarily affects tissues of ectodermal origin, which include the skin, hair, teeth, nails, eyes, and the central nervous system. The skin is almost universally affected, presenting with the characteristic evolving rash and pigmentary changes. Hair can be sparse or patchy, and nails may be brittle, ridged, or absent.
Dental anomalies, such as missing teeth (hypodontia), small or cone-shaped teeth, are common. Ocular involvement can range from mild vision impairment to severe complications like retinal detachment or strabismus (crossed eyes), potentially leading to vision loss. Neurological issues, while less frequent, can include developmental delay, intellectual disability, microcephaly (small head size), and seizures [PMID:33678502].
Risks & severity
Incontinentia pigmenti presents with a wide spectrum of severity. While the skin manifestations are typically present in all affected individuals, the involvement of other organ systems can vary greatly. Some individuals may have only mild skin, hair, and dental issues, while others experience more severe eye or neurological complications. The neurological complications are a significant cause of morbidity for those affected [PMID:20301389].
There is no typical age of onset as the skin symptoms usually appear at birth or during early infancy. The risk of severe outcomes, particularly neurological and ocular, cannot always be predicted early in life. The prognosis for individuals with IP varies considerably depending on the extent of organ involvement. Those without central nervous system or significant ocular disease generally have a normal life expectancy.
Genetic causes
Incontinentia pigmenti is caused by pathogenic variants in the IKBKG gene, also known as NEMO. This gene provides instructions for making a protein that is crucial for the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signalling pathway. The NF-κB pathway plays a vital role in regulating a wide array of cellular processes, including inflammation, immune response, and cell survival [PMID:20301389].
The IKBKG protein acts as a regulatory subunit of the IKK (IκB kinase) complex, which is central to activating NF-κB. Pathogenic variants in IKBKG typically lead to a loss of function of this protein, disrupting the NF-κB pathway. This disruption can result in uncontrolled cell death (apoptosis) in certain tissues, particularly those affected in IP, and contribute to the developmental abnormalities seen in the skin, hair, teeth, eyes, and brain.
- IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
Inheritance pattern
Incontinentia pigmenti is inherited in an X-linked dominant pattern. This means that the IKBKG gene, which is located on the X chromosome, is affected, and only one copy of the altered gene is sufficient to cause the condition. As females have two X chromosomes, they are typically more mildly affected than males, as their second, unaltered X chromosome can often compensate to some extent. However, females will still show symptoms of the condition.
Males have only one X chromosome. If they inherit the altered IKBKG gene, they usually experience a much more severe form of the condition, which is often lethal during embryonic development. For this reason, very few males with IP are born alive. A mother who carries an altered IKBKG gene has a 50% chance of passing it to each child. Daughters who inherit the altered gene will develop IP, and sons who inherit it will typically have a severe, often lethal, form of the condition.
X-linked dominant: all daughters of an affected father inherit the altered X and are affected. Sons receive the father's Y and are unaffected.
Diagnosis & testing
A diagnosis of incontinentia pigmenti is primarily based on clinical signs, particularly the characteristic skin manifestations, and is confirmed by genetic testing. The evolving stages of the skin lesions - from blistering to verrucous growths, then hyperpigmentation, and finally hypopigmentation - are key indicators. Other features like dental abnormalities, sparse hair, or nail changes can support the diagnosis.
Genetic testing for pathogenic variants in the IKBKG gene provides a definitive diagnosis. In the UK, genetic testing for suspected incontinentia pigmenti can be accessed through the NHS Genomic Medicine Service (GMS) under specific clinical indications, generally following referral by a specialist paediatrician, dermatologist, or clinical geneticist. The relevant NHS National Genomic Test Directory R-code for this condition would typically be used to guide testing decisions.
Management & lifestyle
The management of incontinentia pigmenti focuses on monitoring symptoms, preventing complications, and providing supportive care tailored to the individual's specific needs. A multidisciplinary team, which may include dermatologists, ophthalmologists, neurologists, and dentists, is often involved. Regular skin examinations are important to manage any active lesions and to monitor for any changes.
Ophthalmological assessments are crucial, particularly in infancy, to screen for and manage eye abnormalities such as retinal detachment or strabismus, which may require intervention. Neurological development should be monitored, and any developmental delays or seizures would be managed with appropriate therapies and medications. Dental care is essential for addressing abnormalities, and genetic counselling is recommended for affected individuals and their families to understand the inheritance pattern and reproductive risks within the NHS care pathway.
UK care pathway
In the UK, individuals suspected of having incontinentia pigmenti would typically be referred by their GP or another specialist to a clinical genetics service. This service can provide a comprehensive assessment, genetic counselling, and arrange for appropriate genetic testing through the NHS Genomic Medicine Service. The NHS National Genomic Test Directory outlines the available tests, which are guided by specific R-codes for genetic conditions.
Genetic counsellors are key healthcare professionals who can explain the genetic basis of the condition, its inheritance pattern, implications for family members, and assist with navigating the diagnostic and management pathways. They also provide support and information regarding family planning and reproductive options.
Frequently asked questions
Is incontinentia pigmenti only a skin condition?
While incontinentia pigmenti primarily affects the skin, it can also involve other parts of the body. These may include the hair, teeth, nails, eyes, and, in some cases, the central nervous system. The severity of these other manifestations can vary greatly among individuals.
Why is incontinentia pigmenti more common in females?
Incontinentia pigmenti is an X-linked dominant condition. This means males who inherit the altered gene on their single X chromosome are usually severely affected and often do not survive to term. Females have two X chromosomes, so their second, unaffected X chromosome can often help to compensate, leading to a less severe outcome, though they still develop symptoms.
Will my children inherit incontinentia pigmenti?
If you are a female with incontinentia pigmenti, there is a 50% chance with each pregnancy that your child will inherit the altered gene. Daughters who inherit the gene will develop the condition, and sons who inherit it will likely experience a very severe, often lethal, form of the condition. Genetic counselling can provide more personalised information.
Are there any treatments for incontinentia pigmenti?
There is currently no cure for incontinentia pigmenti, but management focuses on treating the specific symptoms and preventing complications. This includes regular monitoring by specialists, managing skin lesions, addressing eye or dental issues, and supporting developmental needs if neurological involvement is present.
What kind of specialist doctors will I need to see for incontinentia pigmenti?
Individuals with incontinentia pigmenti often benefit from care provided by a team of specialists. This may include a dermatologist for skin issues, an ophthalmologist for eye care, a neurologist if there are brain or nerve involvement, and a dentist for any dental abnormalities. Genetic counselling is also an important part of managing the condition.
References
- Poziomczyk CS, Recuero JK, Bringhenti L. Incontinentia pigmenti. Anais brasileiros de dermatologia. 2014. PMID: 24626645
- Pal T, Agrawal S, Grover C. Incontinentia Pigmenti. Indian pediatrics. 2024. PMID: 39001787
- Herzum A, Viglizzo G, Gariazzo L. Neonatal incontinentia pigmenti. Italian journal of dermatology and venereology. 2023. PMID: 36930459
- Francis JS, Sybert VP. Incontinentia pigmenti. Seminars in cutaneous medicine and surgery. 1997. PMID: 9125766
- Zhang LW, Wu J. Incontinentia Pigmenti. Journal of cutaneous medicine and surgery. 2024. PMID: 38268433
- Batson R, Keeling BH, Diaz LZ. Incontinentia Pigmenti. The Journal of pediatrics. 2016. PMID: 27349142
- Al-Farsi N, Al Rashdi A. Incontinentia pigmenti: What we know and can we manage it as retinopathy of prematurity? Oman journal of ophthalmology. 2022. PMID: 36760926
- Özdek Ş, Özdemir Zeydanlı E, Baumal C. Avascular Peripheral Retina in Infants. Turkish journal of ophthalmology. 2023. PMID: 36847634